FTC competition head departs
This article was originally published in The Tan Sheet
Executive Summary
David Wales leaves in May after nine months as acting director of the Federal Trade Commission's Bureau of Competition, the agency says in an April 2 statement. Wales joined FTC in April 2006 as deputy director of the bureau and oversaw cases including the settlement of the Whole Foods and Wild Oats Markets merger, and Inverness Medical Innovations' alleged anticompetitive purchase of a pregnancy test technology (1"The Tan Sheet" Dec. 1, 2008, In Brief and 2"The Tan Sheet" Jan. 5, 2009, p. 14)
You may also be interested in...
Inverness Forced To Release Pregnancy Test Technology
Inverness Medical Innovations must clear a path for the introduction of a water-soluble dye technology for consumer pregnancy tests under a settlement with the Federal Trade Commission
Whole Foods rehearing petition denied
The U.S. Court of Appeals for the District of Columbia Circuit rejects the supermarket chain's request for a rehearing en banc concerning its acquisition of Wild Oats Markets, following the court's July ruling in favor of the Federal Trade Commission, according to a Nov. 21 order. FTC claims the merger between Austin, Texas-based Whole Foods and Boulder, Colo.-based Wild Oats limits competition in the "premium, natural and organic supermarket" segment. "We look forward to presenting our evidence as to why this merger is unlawful" at the administrative trial before the commission, scheduled for Feb. 16, says David Wales, FTC's Bureau of Competition acting director. Wales adds the agency wants to maintain competition and reach "a meaningful remedy." FTC indicated interest in settling, though Whole Foods may seek certiorari before the Supreme Court, which has shown pro-merger sentiments (1"The Tan Sheet" Aug. 18, 2008, p. 6)
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.